Two innovative, forward-thinking organizations show how rebuilding patient trust is becoming the real breakthrough driving ...
Firm says its work with a biotech client could signal a sea change in how - and when - law firms enter the drug development ...
BUFFALO, N.Y. — The University at Buffalo’s Spotlight Symposia Series returns this weekend to honor Soo-Kyung Lee, director of the FOXG1 Research Center at UB, a parent of a child with FOXG1 syndrome ...
Citizen Health co-founders Farid Vij and Nasha Fitter created a new AI-powered platform to provide relief to patients and families navigating rare and complex conditions. Citizen Health, which has ...
A Buffalo family is showing what is possible when parents use their skills to improve outcomes for their children with disabilities. Soo-Kyung Lee, and her husband, Jae Lee, were both scientists ...
BUFFALO, N.Y. — A drug developed at the University at Buffalo to treat FOXG1 syndrome has been cleared by the U.S. Food and Drug Administration (FDA) to begin clinical trials. The agency approved an ...
Two weeks ago, ESPN's College GameDay featured Georgia tight end Lawson Luckie, and how his journey to Athens was not only forged as the son of a former player, but as the older brother of Cannon, who ...
This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...
TAIPEI (Taiwan News) — National Yang Ming Chiao Tung University and National Taiwan University Children's Hospital have collaborated to develop a test that predicts the severity of the rare FOXG1 ...
This guest essay reflects the views of Scott D. Reich, of Port Washington, whose nonprofit is developing a treatment for FOXG1 syndrome while providing support to the broader rare disease community.
“What we noticed was that Yuna cried a lot,” Dr Lee says. “Day and night, Yuna cried and she didn’t sleep much. When we took her to clinics, we were told ‘some babies just cry a lot’. But then we ...